therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
25 Apr 2017
Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017 MORE
21 Mar 2017
Amarin Corporation CEO, John Thero, to Chair the American Heart Association's Heart & Stroke Ball in New York City MORE
- AMRN (NASDAQ)
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.